Nektar Therapeutics Q3 2026 Earnings Date & Estimates

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company focused on discovering and developing medicines that use the body’s immune system to treat cancer and autoimmune diseases. The company’s research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.

Nektar’s pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses. The company has also developed rezpegaldesleukin, an investigational therapy intended to selectively expand regulatory T cells for the treatment of autoimmune and inflammatory diseases. These and other candidates remain subject to clinical testing and regulatory review.

Founded in 1990 and headquartered in San Francisco, Nektar has historically used partnerships with larger pharmaceutical companies to advance and commercialize products based on its technology. Its earlier portfolio and collaborations included medicines such as Movantik, a treatment for opioid-induced constipation, as well as other products using the company’s polymer-conjugation and drug-delivery expertise. Nektar’s research and clinical activities serve patients and healthcare markets internationally.

Howard W. Robin has served as Nektar Therapeutics’ president and chief executive officer. The company’s operations are primarily centered on research, clinical development, and strategic collaborations in oncology and immunology.